Brineura Patient Ambulation Equipment
1 equipment items found
-
Manufactured by BioMarinbased in USA
The first approved treatment for any form of Batten disease. Brineura (cerliponase alfa) is indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency. Brineura is the first ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you